title: Response to Comment on "Cutting Edge: Inhibiting TBK1 by Compound II Ameliorates Autoimmune Disease in Mice".
authors.affiliation: Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland;
authors.forename: Maroof
authors.identifier: http://orcid.org/0000-0003-4640-6949
authors.initials: M
authors.lastname: Hasan
authors.affiliation: Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390; and Department of Microbiology, University of Texas Southwestern Medical Center, Dallas, TX 75390 nan.yan@utsouthwestern.edu.
authors.forename: Nan
authors.initials: N
authors.lastname: Yan
mesh_terms: D000818:Animals; D001327:Autoimmune Diseases / Q000188:drug therapy*; D006801:Humans; D007372:Interferons / Q000276:immunology*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors*
chemical_list: D047428:Protein Kinase Inhibitors; D007372:Interferons; D017346:Protein Serine-Threonine Kinases